I wonder how the Parexel and ICON locking up Pfizer's work is going over at Quintiles. With InVentiv's purchase of Pharmanet and i3, it puts them in revenue ranks of Parexel and ICON (pre-Pfizer deal). INC and Kendle merger gives them a bigger global footprint, but didn't really make them jump up very high in the rankings. I think CRO revenue rank is probably: 1) Quintiles 2) PPD 3) Covance 4) ICON 5) Parexel 6) Inventiv 7) INC/Kendle 8) PRA 9) Chiltern i might be missing somebody
looks like a good list. the 9th and 10th spot could be PSI, Pharm-Olam, Medpace, Chiltern, Premier Research and maybe Clinsys.... Probably two or three of these guys will hook up to compete. Who cares about Pfizer. Their margins are so low, they will always be awarded to tier 2 providers as Q and PPD would rather go after high margin/less pain in the buttocks stuff (emerging biotech and mid pharm stuff)....IMHO....
if the second poster really believes PPD and Quintiles didn't want to get selected by Pfizer, I think you're incorrect. Quintiles was eager to get that work.
